Patents by Inventor Christine AHLSTRÖM

Christine AHLSTRÖM has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20230364077
    Abstract: The present disclosure relates to the endothelin receptor antagonist (ERA) zibotentan in combination with the sodium-dependent glucose cotransporter 2 (SGLT-2) inhibitor dapagliflozin for use in the treatment of certain endothelin related diseases.
    Type: Application
    Filed: June 23, 2023
    Publication date: November 16, 2023
    Inventors: Peter GREASLEY, Christine AHLSTRÖM, Stanko SKRTIC, Robert MENZIES, Anne-Kristina MERCIER, Mikael SUNNÅKER
  • Patent number: 11730735
    Abstract: The present disclosure relates to the endothelin receptor antagonist (ERA) zibotentan in combination with the sodium-dependent glucose cotransporter 2 (SGLT-2) inhibitor dapagliflozin for use in the treatment of certain endothelin related diseases.
    Type: Grant
    Filed: July 9, 2021
    Date of Patent: August 22, 2023
    Assignee: ASTRAZENECA AB
    Inventors: Peter Greasley, Christine Ahlström, Stanko Skrtic, Robert Menzies, Anne-Kristina Mercier, Mikael Sunnåker
  • Publication number: 20220023295
    Abstract: The present disclosure relates to the endothelin receptor antagonist (ERA) zibotentan in combination with the sodium-dependent glucose cotransporter 2 (SGLT-2) inhibitor dapagliflozin for use in the treatment of certain endothelin related diseases.
    Type: Application
    Filed: July 9, 2021
    Publication date: January 27, 2022
    Inventors: Peter GREASLEY, Christine AHLSTRÖM, Stanko SKRTIC, Robert MENZIES